ARX517 Demonstrates Early Efficacy With Favorable Safety in Heavily Pretreated mCRPC
ARX517 displayed preliminary efficacy and a strong safety profile in patients with metastatic castration-resistant prostate cancer, according to findings from the phase 1/2 APEX-01 study.
United States John Shen Los Angeles Oncology Department At Jonsson Comprehensive Cancer Center Medical Oncology Department Jonsson Comprehensive Cancer Center
Source: onclive.com